Cargando...
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. No...
Guardado en:
| Publicado en: | Therap Adv Gastroenterol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622287/ https://ncbi.nlm.nih.gov/pubmed/26557893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X15592586 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|